Linlin Li1, Xutao Deng1, Antonio Charlys Da Costa2, Roberta Bruhn3, Steven G Deeks4, Eric Delwart5. 1. Blood Systems Research Institute, San Francisco, CA, USA; Department of Laboratory Medicine, University of California, San Francisco, CA, USA. 2. Blood Systems Research Institute, San Francisco, CA, USA; Institute of Tropical Medicine, School of Medicine, University of São Paulo, São Paulo, Brazil. 3. Blood Systems Research Institute, San Francisco, CA, USA. 4. Positive Health Program, San Francisco General Hospital, San Francisco, CA, USA. 5. Blood Systems Research Institute, San Francisco, CA, USA; Department of Laboratory Medicine, University of California, San Francisco, CA, USA. Electronic address: delwarte@medicine.ucsf.edu.
Abstract
BACKGROUND: Abnormally high levels of T-cell activation can persist in HIV-infected subjects despite effective anti-retroviral therapy (ART) and has been associated with negative health outcomes. The nature of the antigenic drivers or other causes of this residual T-cell activation remain uncertain. Anelloviruses are universally acquired soon after birth, resulting in persistent viremia, and considered part of the commensal human virome. Reduced immunocompetence results in increased anellovirus levels. OBJECTIVES: To test whether increased levels of anelloviruses or other viruses in plasma are associated with higher levels of persistent T-cell activation during ART. STUDY DESIGN: Two amplification methods combined with next generation sequencing were used to detect all viruses and estimate relative anellovirus levels in plasma from 19 adults on effective ART who exhibited a wide range of T-cell activation levels. RESULTS: Nucleic acids from HBV and HCV were detected in one patient each while pegivirus A (GBV-C) was found in three patients. Anellovirus DNA was detected in all patients with some individuals carrying up to eight different genotypes. Specific anellovirus genotypes or higher level of co-infections were not detected in subjects with higher levels of T-cell activation. No association was detected between relative plasma anellovirus DNA levels and the percentage of activated CD4 or CD8 T cells. CONCLUSIONS: Human anelloviruses were detected in all HIV suppressed subjects, exhibited a wide range of viremia levels, and were genetically highly diverse. The level of persistent T-cell activation was not correlated with the level of viremia or genotypes present indicating that anellovirus antigens are unlikely to be a dominant source of antigens driving chronic T-cell activation.
BACKGROUND: Abnormally high levels of T-cell activation can persist in HIV-infected subjects despite effective anti-retroviral therapy (ART) and has been associated with negative health outcomes. The nature of the antigenic drivers or other causes of this residual T-cell activation remain uncertain. Anelloviruses are universally acquired soon after birth, resulting in persistent viremia, and considered part of the commensal human virome. Reduced immunocompetence results in increased anellovirus levels. OBJECTIVES: To test whether increased levels of anelloviruses or other viruses in plasma are associated with higher levels of persistent T-cell activation during ART. STUDY DESIGN: Two amplification methods combined with next generation sequencing were used to detect all viruses and estimate relative anellovirus levels in plasma from 19 adults on effective ART who exhibited a wide range of T-cell activation levels. RESULTS: Nucleic acids from HBV and HCV were detected in one patient each while pegivirus A (GBV-C) was found in three patients. Anellovirus DNA was detected in all patients with some individuals carrying up to eight different genotypes. Specific anellovirus genotypes or higher level of co-infections were not detected in subjects with higher levels of T-cell activation. No association was detected between relative plasma anellovirus DNA levels and the percentage of activated CD4 or CD8 T cells. CONCLUSIONS:Human anelloviruses were detected in all HIV suppressed subjects, exhibited a wide range of viremia levels, and were genetically highly diverse. The level of persistent T-cell activation was not correlated with the level of viremia or genotypes present indicating that anellovirus antigens are unlikely to be a dominant source of antigens driving chronic T-cell activation.
Authors: A S Muerhoff; J N Simons; T P Leary; J C Erker; M L Chalmers; T J Pilot-Matias; G J Dawson; S M Desai; I K Mushahwar Journal: J Hepatol Date: 1996-09 Impact factor: 25.083
Authors: Jeanette Kluba; Silvia Linnenweber-Held; Albert Heim; Angella M Ang; Lubna Raggub; Verena Broecker; Jan U Becker; Thomas F Schulz; Anke Schwarz; Tina Ganzenmueller Journal: Intervirology Date: 2015-02-13 Impact factor: 1.763
Authors: Chris D Madsen; Jesper Eugen-Olsen; Ole Kirk; Jan Parner; Jens Kaae Christensen; Marie S Brasholt; Jens Ole Nielsen; Kim Krogsgaard Journal: HIV Clin Trials Date: 2002 Jul-Aug
Authors: Antoinette C van der Kuyl; Fokla Zorgdrager; Boris Hogema; Margreet Bakker; Suzanne Jurriaans; Nicole K T Back; Ben Berkhout; Hans L Zaaijer; Marion Cornelissen Journal: BMC Infect Dis Date: 2013-11-14 Impact factor: 3.090
Authors: Joshua A Blatter; Stuart C Sweet; Carol Conrad; Lara A Danziger-Isakov; Albert Faro; Samuel B Goldfarb; Don Hayes; Ernestina Melicoff; Marc Schecter; Gregory Storch; Gary A Visner; Nikki M Williams; David Wang Journal: Pediatr Transplant Date: 2017-10-29
Authors: Brett Williams; Mimi Ghosh; Charles Boucher; Frederic Bushman; Stacy Carrington-Lawrence; Ronald G Collman; Satya Dandekar; Que Dang; Angela Malaspina; Roger Paredes; Cara Wilson; Sandra Pinto Cardoso; Laurel Lagenaur; Jessica Santos; Christopher Joy; Alan Landay Journal: AIDS Res Hum Retroviruses Date: 2020-03-09 Impact factor: 2.205
Authors: A Fuchs; N Lübke; L Schmidt; B-E O Jensen; A Walker; V Keitel-Anselmino; V di Cristanziano; M Böhm; E Knops; E Heger; R Kaiser; A de Luca; M Oette; D Häussinger; J Timm Journal: Infection Date: 2021-02-03 Impact factor: 3.553
Authors: Rafal Tokarz; Jeffrey S Hyams; David R Mack; Brendan Boyle; Anne M Griffiths; Neal S LeLeiko; Cary G Sauer; Sapana Shah; James Markowitz; Susan S Baker; Joel Rosh; Robert N Baldassano; Subra Kugathasan; Thomas Walters; Teresa Tagliafierro; Stephen Sameroff; Bohyun Lee; Xiaoyu Che; Alexandra Oleynik; Lee A Denson; W Ian Lipkin Journal: Inflamm Bowel Dis Date: 2019-09-18 Impact factor: 5.325
Authors: Savannah Mwesigwa; Lesedi Williams; Gaone Retshabile; Eric Katagirya; Gerald Mboowa; Busisiwe Mlotshwa; Samuel Kyobe; David P Kateete; Eddie Mujjwiga Wampande; Misaki Wayengera; Sununguko Wata Mpoloka; Angella N Mirembe; Ishmael Kasvosve; Koketso Morapedi; Grace P Kisitu; Adeodata R Kekitiinwa; Gabriel Anabwani; Moses L Joloba; Enock Matovu; Julius Mulindwa; Harry Noyes; Gerrit Botha; Chester W Brown; Graeme Mardon; Mogomotsi Matshaba; Neil A Hanchard Journal: NPJ Genom Med Date: 2021-03-19 Impact factor: 8.617